Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 811,773 | 535,203 | 920,359 | 646,508 | 604,214 |
| Marketable Securities | 495,311 | 503,481 | 488,032 | 398,656 | 244,965 |
| Receivables | 1,749,548 | 1,611,620 | 1,643,872 | 1,751,971 | 1,865,221 |
| Inventories | 466,576 | 399,356 | 345,620 | 316,073 | 303,294 |
| TOTAL | $3,669,263 | $3,180,188 | $3,501,689 | $3,209,225 | $3,133,379 |
| Non-Current Assets | |||||
| PPE Net | 2,277,029 | 2,083,421 | 1,872,167 | 1,772,923 | 1,666,391 |
| Investments And Advances | 967,695 | 864,260 | 777,906 | 589,852 | 555,210 |
| Other Non-Current Assets | 903,378 | 845,597 | 676,257 | 632,906 | 549,480 |
| TOTAL | $4,148,102 | $3,793,278 | $3,326,330 | $2,995,681 | $2,771,081 |
| Total Assets | $7,817,365 | $6,973,466 | $6,828,019 | $6,204,906 | $5,904,460 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,061,777 | 879,096 | 714,916 | 759,643 | 733,276 |
| Other current liabilities | 876 | 1,178 | 3,586 | 3,695 | 13,508 |
| TOTAL | $1,308,271 | $1,241,495 | $961,185 | $951,563 | $919,724 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 238,418 | 231,664 | 242,683 | 188,225 | 172,940 |
| aiOther Non-Current Liabilities | 106,248 | 100,385 | 135,700 | 119,523 | 120,993 |
| TOTAL | $1,643,073 | $1,282,726 | $1,375,587 | $1,176,837 | $1,219,654 |
| Total Liabilities | $2,951,344 | $2,524,221 | $2,336,772 | $2,128,400 | $2,139,378 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 106,291 | 106,081 | 105,470 | 105,295 | 105,079 |
| Common Shares | 110 | 110 | 109 | 109 | 109 |
| Retained earnings | 1,997,153 | 1,748,222 | 1,495,107 | 1,230,303 | 1,018,436 |
| Other shareholders' equity | -6,124 | -13,080 | -2,951 | 5,152 | 3,886 |
| TOTAL | $4,866,021 | $4,449,245 | $4,491,247 | $4,076,506 | $3,765,082 |
| Total Liabilities And Equity | $7,817,365 | $6,973,466 | $6,828,019 | $6,204,906 | $5,904,460 |